CSV February 22, 2023 through February 22, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RESIDUAL	1. INTRODUCT	*USPNF Online*	Online	31-Jan-2025	1-May-2025	*NA*	*NA*	In paragraph 3:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HOST CELL PROTEIN MEASUREMENT IN BIOPHARMACEUTICALS BY LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY	ION AND SCOPE							Change Residual HCP ELISA to: HCP ELISA
RESIDUAL HOST CELL PROTEIN MEASUREMENT IN BIOPHARMACEUTICALS BY LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY	7. BEST PRACTICES FOR REPORTING DATA FROM ELISA VERSUS LC-MS/MS	*USPNF Online*	Online	31-Jan-2025	1-May-2025	*NA*	*NA*	In paragraph 1 in *7.3 Comparison of ELISA and LC-MS/MS HCP Results*: Change the comparing to: comparing
RESIDUAL HOST CELL PROTEIN MEASUREMENT IN BIOPHARMACEUTICALS BY LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY	4. SAMPLE PREPARATION, CHROMATOGRAPHIC SEPARATION, AND MASS SPECTROMETRY ANALYSIS	*USPNF Online*	Online	31-Jan-2025	1-May-2025	*NA*	*NA*	In paragraph 4 in *4.1 Sample Preparation*: Change product (or polysorbate) to: product protein (or polysorbate)
HYDROXYPROPYL BETADEX	IMPURITIES	*USPNF Online*	Online	31-Jan-2025	1-Feb-2025	*NA*	*NA*	In *Limit of Betadex,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Propylene Glycol, and Other Related Sub stances/ Chromatographi c system: Change **Column temperature:** 40° to: **Temperatures Detector:** 40° **Columns:** 40°
RESIDUAL HOST CELL PROTEIN MEA SUREMENT IN BIOPHARMAC EUTICALS BY LIQUID CHRO MATOGRAPHY –MASS SPECT ROMETRY	5. QUANTITATI ON OF HCPS	*USPNF Online*	Online	31-Jan-2025	1-May-2025	*NA*	*NA*	In three instances in *5.1 Methods for HCP Quantitation*: Change product to: product protein
DIBUCAINE	CHROMATOG RAPHIC PURITY	*USPNF Online*	Online	27-Dec-2024	1-Jan-2025	*NA*	*NA*	Change Proceed as directed for *Chromatographi c purity* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OXALIPLATIN	IMPURITIES	*USPNF Online*	Online	27-Dec-2024	1-Jan-2025	*NA*	*NA*	*Dibucaine Hydrochloride*, to: Proceed as directed for *Organic Impurities* under *Dibucaine Hydrochloride*, In *Organic Impurities, Procedure 1*/*Analysis*: Change Result = $(r_U/r_S) \times (C_S/(C_U) \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$
ACESULFAME POTASSIUM	SPECIFIC TESTS	*USPNF Online*	Online	27-Dec-2024	1-Jan-2025	*NA*	*NA*	In *Acidity or Alkalinity*/*Analysis*: Change If the solution is blue, titrate with 0.01 N hydrochloride acid to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								If the solution is blue, titrate with 0.01 N hydrochloric acid
INDOMETHACIN SODIUM	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	22-Nov-2024	1-Dec-2024	*NA*	*NA*	In *USP Reference Standards ?11?*/USP Indomethacin Related Compound A RS: Change ($C_{12}H_{13}NO_3$) to: $C_{12}H_{13}NO_3$ AND In *USP Reference Standards ?11?*/USP Indomethacin Related Compound B RS: Change ($C_7H_5ClO_2$) to: $C_7H_5ClO_2$
TAMSULOSIN HYDROCHLORIDE	ASSAY	*USPNF Online*	Online	22-Nov-2024	1-Dec-2024	*NA*	*NA*	In *Procedure 1/Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES								C_S = concentration of USP Tamsulosin Hydrochloride RS in the *Standard stock solution* (mg/mL) to: C_S = concentration of USP Tamsulosin Hydrochloride RS in the *Standard solution* (mg/mL)
TAMSULOSIN HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS	*USPNF Online*	Online	22-Nov-2024	1-Dec-2024	*NA*	*NA*	In *Dissolution ?711?/Test 1/Analysis*: Change $Result_3 = \{[(C_3 \times V_2) + (C_2 + V_S)] \times (1/L) \times 100\} + Result_1$ to: $Result_3 = \{[(C_3 \times V_2) + (C_2 \times V_S)] \times (1/L) \times 100\} +$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUCONAZOLE	IMPURITIES	*USPNF Online*	Online	25-Oct-2024	1-Nov-2024	*NA*	*NA*	$Result_1$ In *Organic Impurities/Analysis*: Change Calculate the percentage of any individual unspecified impurity in the portion of Fluconazole taken: to: Calculate the percentage of any other specified and unspecified impurity in the portion of Fluconazole taken: AND Change r_U = peak response of any individual impurity from the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: r_U = peak response of any other specified and unspecified impurity from the *Sample solution*
ALUMINUM SULFATE	CHEMICAL INFORMATION	*USPNF Online*	Online	25-Oct-2024	1-Nov-2024	*NA*	*NA*	Change $Al_2(SO_4)_3 \cdot xH_2O$ (anhydrous) 342.15 to: $Al_2(SO_4)_3 \cdot xH_2O$ AND Change Anhydrous 342.16 to: Anhydrous 342.13
CALCITONIN SALMON	SPECIFIC TESTS	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Bioidentity*/*Medium B*: Change 2 mM *RPMI 1640* to: *RPMI 1640*
METHOTREXA	ASSAY	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TE								*Proce dure*/*Buffer*: Correct the reagent cross reference 1 N sodium hydroxide to: 1 N sodium hydroxide
RALBUMIN HUMAN	IMPURITIES	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Limit of High Molecular Weight Proteins*: Change **Acceptance criteria Individual impurities:** NMT 1.0% to: **Acceptance criteria:** NMT 1.0%
AMLODIPINE AND BENAZEPRIL H YDROCHLORI DE CAPSULES	ASSAY	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Proce dure*/*Buffer 1*: Change tetrabutyl ammonium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: tetrabutylammonium
FLUCONAZOLE TABLETS	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *USP Reference Standards <11>*/USP Fluconazole Related Compound B RS: Change $C_{13}H_{13}FN_9O$ to: $C_{13}H_{13}FN_6O$
PHENOXYBENZAMINE HYDROCHLORIDE	ASSAY	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Procedure*/*Solution A*: Change sodium phosphate monobasic to: sodium phosphate, monobasic, anhydrous
CETIRIZINE HYDROCHLORIDE	IMPURITIES	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Organic Impurities, Procedure 2*/*Solution A*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								tetrabutyl ammonium to: tetrabutylammonium
MOXIFLOXACIN TABLETS	IMPURITIES	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Organic Impurities*/*Buffer*: Change tetrabutyl ammonium to: tetrabutylammonium AND In *Organic Impurities*/*Solution C*: Change tetrabutyl ammonium to: tetrabutylammonium
CALCITONIN SALMON	IMPURITIES	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Procedure: Related Peptides and Other Related Substances*/*Test 2*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
KETOCONAZO ASSAY LE		*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	**Resolution solution:** to: **System suitability solution:** AND In *Procedure: Related Peptides and Other Related Sub stances*/*Test 2*/*Sample solution*: Change 100 mL of *Buffer C*. to: 100 ?L of *Buffer C*. In *Proce dure*/*Buffer*: Change tetrabutyl ammonium to: tetrabutylammo nium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RALBUMIN HUMAN	ASSAY	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Albumin Content*/*Native stock running buffer*: Change glycerol to: glycine
ADENOSINE	ASSAY	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Procedure*/*Buffer*: Change tetrabutyl ammonium to: tetrabutylammonium
CETIRIZINE HYDROCHLORIDE TABLETS	IMPURITIES	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Organic Impurities*/*Buffer*: Change tetrabutyl ammonium to: tetrabutylammonium
PACLITAXEL	IMPURITIES	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Organic Impurities*/*Table 4*: Change [a](2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,12b*S*)-12b-(Acetyloxy)-12-(benzyloxy)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-4,6,9,11-tetrahydroxy-4a,8,13,13-tetramethyl-
								H-cyclodeca[3,4]benz[1,2-*b*]oxet-5-one. to: [a](2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-12b-(Acetyloxy)-12-(benzoyloxy)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-4,6,9,11-tetrahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-cyclodeca[3,4] benz[1 ,2-*b*]oxet-5-one.
POTASSIUM PHOSPHATES COMPOUNDED INJECTION	ASSAY	*USPNF Online*	Online	30-Aug-2024	1-Sep-2024	*NA*	*NA*	In *Procedure for Potas sium/ Chromatographic system/Column*: Change 4.6-mm × 25-cm; packing L97 to: 4-mm × 25-cm; packing L97 AND In *Procedure for Phos phate/ Chromatographic system/Column*: Change 4.6-mm × 25-cm; packing L103 to: 4-mm × 25-cm; packing L103
NICARDIPINE	ADDITIONAL R	*USPNF Online*	Online	26-Jul-2024	1-Aug-2024	*NA*	*NA*	In *USP*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE	EQUIREMENTS							*Reference Standards* <*11*>/USP Nicardipine Related Compound B RS: Change 3-{2-[Benzyl(methyl)amino]ethyl }5-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate oxalate. to: 3-{2-[Benzyl(methyl)amino]ethyl } 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate oxalate. AND In *USP Reference Standards* <*11*>/USP Nicardipine Related Compound D RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Bis{2-[benzyl(methyl)amino]ethyl}2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate dihydrochloride. to: Bis{2-[benzyl(methyl)amino]ethyl} 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate dihydrochloride.
EXENATIDE INJECTION	PRODUCT-RELATED SUBSTANCES AND IMPURITIES	*USPNF Online*	Online	26-Jul-2024	1-Aug-2024	*NA*	*NA*	In *Procedure/Chromatographic system/Column*: Change 4.6-mm × 10-cm; 3-µm packing L52 to: 4.6-mm × 10-cm; 3-µm packing L52;

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								two columns in series
CRANBERRY FRUIT JUICE DRY EXTRACT	IDENTIFICATION	*USPNF Online*	Online	26-Jul-2024	1-Aug-2024	*NA*	*NA*	In *A. HPTLC for Articles of Botanical Origin <203>*/*Sample solution*: Change Mix 50 mg of Cranberry Fruit Juice Dry Extract with 7 mL of water. Sonicate for 10 min at room temperature, centrifuge, and save the supernatant. Precondition an SPE cartridge (L2; 500 mg/6 mL) with 3 mL of methanol, and drain it with suction. Load 3 mL of water onto the cartridge and apply suction until the solvent

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								reaches 1–2 mm above the top of the cartridge's stationary phase. Then load the cartridge with 1.5 mL of the supernatant, apply suction, and discard the eluate. Add 1 mL of a mixture of water and methanol (80:20). Load 1 mL of methanol and collect the eluate as the *Sample solution*. to: Mix 50 mg of Cranberry Fruit Juice Dry Extract with 7 mL of water. Sonicate for 10 min at room temperature,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								centrifuge, and save the supernatant. Precondition an SPE cartridge (L2; 500 mg/6 mL) with 3 mL of methanol, and drain it with suction. Load 3 mL of water onto the cartridge and apply suction until the solvent reaches 1–2 mm above the top of the cartridge's stationary phase. Then load the cartridge with 1.5 mL of the supernatant, apply suction, and discard the eluate. Add 1 mL of a mixture of water and methanol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(80:20), apply suction, and discard the eluate. Load 1 mL of methanol and collect the eluate as the *Sample solution*.
NAPROXEN SODIUM	SPECIFIC TESTS	*USPNF Online*	Online	28-Jun-2024	1-Aug-2024	*NA*	*NA*	In *Loss on Drying <731>/Analysis*: Change Dry at 105° for 3 h. to: Dry in vacuum at 105° for 3 h.
EDETATE DISODIUM COMPOUNDED OPHTHALMIC SOLUTION	DEFINITION	*USPNF Online*	Online	28-Jun-2024	1-Jul-2024	*NA*	*NA*	In two instances: Change to a pH between 6.5 and 7.5. to: to a pH between 6.1 and 7.1.
DESCRIPTION AND SOLUBILITY	Hydrogenated Castor Oil	*USPNF Online*	Online	28-Jun-2024	1-Aug-2026	*NA*	*NA*	Change White, crystalline wax.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Freely soluble in water, in saline TS, and in dextrose solutions; very slightly soluble in alcohol; practically insoluble in chloroform and in ether. Insoluble in water and in most common organic solvents. *NF category*: Stiffening agent; lubricant; film-forming agent; r elease-modifying agent. to: White, crystalline wax. Insoluble in water and in most common organic solvents. *NF*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								category: Stiffening agent; lubricant; film-forming agent; release-modifying agent.
NEOMYCIN AND POLYMYXIN B SULFATES AND LIDOCAINE CREAM	ASSAY	*USPNF Online*	Online	28-Jun-2024	1-Jul-2024	*NA*	*NA*	Change **Assay for neomycin—**Proceed with Cream as directed in the *Assay for neomycin* under *Neomycin and Polymyxin B Sulfates Cream*. **Assay for polymyxin B—**Proceed with Cream as directed in the *Assay for polymyxin B* under *Neomycin and Polymyxin B Sulfates Cream*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: **Assay for ne omyc in—**Proceed as directed under *Antibiotics—Micr obial Assays* ?81?, using an accurately weighed portion of Cream, equivalent to about 1.75 mg of neomycin, shaken in a separator with about 50 mL of ether, and extracted with four 20-mL portions of *Buffer B.3*. Combine the aqueous extracts, and dilute with *Buffer B.3* to an appropriate volume to obtain a stock

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution of convenient concentration. Dilute this stock solution quantitatively and stepwise with *Buffer B.3* to obtain a *Test Dilution* having a concentration assumed to be equal to the median dose level of the Standard. **Assay for polymyxin B—**Proceed as directed under *Antibiotics—Microbial Assays* ?81?, using an accurately weighed portion of Cream shaken with about 50 mL of ether in a separator, and extracted with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								four 25-mL portions of *Buffer B.6*. Combine the aqueous extracts, and dilute with *Buffer B.6* to an appropriate volume to obtain a stock solution. Dilute this stock solution quantitatively and stepwise with *Buffer B.6* to obtain a *Test Dilution* having a concentration assumed to be equal to the median dose level of the Standard (10 Polymyxin B Units per mL). Add to each test dilution of the Standard a quantity of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Neomycin Sulfate RS, dissolved in *Buffer B.6*, to obtain the same concentration of neomycin present in the *Test Dilution*.
TYLOSIN INJECTION	SPECIFIC TESTS	*USPNF Online*	Online	31-May-2024	1-Jun-2024	*NA*	*NA*	Change *pH* ?921? to: *pH* ?791?
CEFUROXIME AXETIL FOR ORAL SUSPENSION	ASSAY	*USPNF Online*	Online	31-May-2024	1-Jun-2024	*NA*	*NA*	In *Procedure*/*System suitability*: Change [Note—The relative retention times for acetanilide, cefuroxime axetil diastereoisomer B, cefuroxime axetil diastereoisomer A, and cefuroxime axetil delta-3

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								isomers are 0.4, 0.8, 0.9, and 1.0, respectively.] to: [Note—The relative retention times for cefuroxime axetil diastereoisomer B, cefuroxime axetil diastereoisomer A, and cefuroxime axetil delta-3 isomers are 0.8, 0.9, and 1.0, respectively.]
METRONIDAZOLE CAPSULES	IMPURITIES	*USPNF Online*	Online	31-May-2024	1-Jun-2024	*NA*	*NA*	In *Organic Impurities*: Change **Mobile phase**, **Sample solution**, and **Chromatographic system:** Proceed as directed in the *Assay*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: **Mobile phase** and **Chromatographic system:** Proceed as directed in the *Assay*. AND Change **Standard solution:** 1 µg/mL of metronidazole from USP Metronidazole RS and 2 µg/mL of tinidazole related compound A from USP Tinidazole Related Compound A RS in *Mobile phase* to: **Standard solution:** 1 µg/mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								metronidazole from USP Metronidazole RS and 2 µg/mL of tinidazole related compound A from USP Tinidazole Related Compound A RS in *Mobile phase* **Sample soluti on:** Nominally 1 mg/mL of metronidazole prepared as follows. Mix the contents of Capsules (NLT 20). Transfer an amount equivalent to 100 mg of metronidazole to a 100-mL volumetric flask, add 80 mL of *Mobile phase*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and sonicate with intermittent shaking for 10 min. Shake for 30 min, and dilute with *Mobile phase* to volume. Centrifuge a portion of the solution.
PROCAINAMIDE HYDROCHLORIDE	ASSAY	*USPNF Online*	Online	31-May-2024	1-Jun-2024	*NA*	*NA*	In *Resolution solution*: Change *p*-aminobenzoic acid to: *p*-aminobenzoic acid
DOCETAXEL	IMPURITIES	*USPNF Online*	Online	31-May-2024	1-Jun-2024	*NA*	*NA*	In *Organic Impurities*, *Procedure 1*: Change **System suitability solution, Standard solution, Sample solution,** and **Chromatograp**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hic system: Proceed as directed in the *Assay*. to: **Mobile phase, Diluent, System suitability solution, Standard solution, Sample solution,** and **Chromatograp hic system:** Proceed as directed in the *Assay*.
RIVASTIGMINE TARTRATE	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *USP Reference Standards* ?11?: Change USP Rivastigmine Tartrate R-Isomer RS to: USP Rivastigmine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Tartrate R-Isomer RS (*R*)-3-[1-(Dimethylamino)ethyl]phenyl ethylmethylcarbamate, hydrogen tartrate. $C_{14}H_{22}N_2O_2 \cdot C_4H_6O_6$ 400.42
DOXORUBICIN HYDROCHLORIDE	ASSAY	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Procedure*/*System suitability solution*: Add link to USP Store for USP Epirubicin Hydrochloride RS
DILUTED ISOSORBIDE MONONITRATE	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Organic Impurities*/*Standard solution*: Change isosorbide related compound A to: isosorbide mon

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								onitrate related compound A AND In *System suitability/Suitability requirements/Relative standard deviation*: Change isosorbide related compound A, to: isosorbide mononitrate related compound A, AND In four instances in *Analysis*: Change isosorbide related compound A, to: isosorbide mononitrate related compound A,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND In *Table 1*: Change Isosorbide related compound A to: Isosorbide mononitrate related compound A
BROMPHENIRAMINE MALEATE	SPECIFIC TESTS	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	Change **Optical Rotation** ?781? to: **Optical Rotation**, *Angular Rotation* ?781A?
RIVASTIGMINE TARTRATE	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Organic Impurities/Procedure 1/Impurity Table 1*/footnote d: Change 3-Nitrophenyl ethyl(methyl)carbamate. to: 4-Nitrophenyl et

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hyl(methyl)carbamate.
ISOSORBIDE MONONITRATE TABLETS	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Organic Impurities*/*Standard solution*: Change isosorbide related compound A to: isosorbide mononitrate related compound A AND In *System suitability*/*Suitability requirements*/*Relative standard deviation*: Change isosorbide related compound A, to: isosorbide mononitrate related compound A,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DAPSONE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	AND In four instances in *Analysis*: Change isosorbide related compound A, to: isosorbide mononitrate related compound A, AND In *Table 1*: Change Isosorbide related compound A to: Isosorbide mononitrate related compound A In *Dissolution* ?711?/*Standard solution*: Change USP Dapsone RS of a known concentration in *Medium* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LIDOCAINE	ASSAY	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	(*L*/1000) mg/mL of USP Dapsone RS in *Medium*, where *L* is the label claim in mg/Tablet. Transfer a portion of this solution containing 0.2 mg of dapsone to a 25-mL volumetric flask, add 5 mL of 1 N sodium hydroxide, and dilute with water to volume. In *Procedure*: Change **Column:** 3.9-mm × 30-cm; 4-µm packing L1 to: **Column:** 3.9-mm × 30-cm; 10-µm packing L1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ENSULIZOLE	IDENTIFICATION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *B*.: Change The retention time of the major peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the *Standard solution*, as obtained in the *Assay*. to: The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
LIDOCAINE, RACEPINEPHRINE AND TETRACAINE	DEFINITION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	Change Prepare Lidocaine, Racepinephrine, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDES COMPOUNDED TOPICAL GEL								Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Sterile Preparations* <797>). to: Prepare Lidocaine, Racepinephrine, and Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Nonsterile Preparations* <795>).

Pagination

- Page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »